MetaCap

Gyre Therapeutics (GYRE) vs Shattuck Labs (STTK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Shattuck Labs (STTK) has outperformed Gyre Therapeutics (GYRE) over the past year, gaining 119.7% versus a loss of 44.2%. Over five years, STTK leads with a -52.0% price change compared with -77.5% for GYRE. Gyre Therapeutics is the larger company by market cap ($460.8 million vs $454.2 million), about 1.0 times the size.

Gyre Therapeutics converts more of its revenue into profit, with a net margin of 8.5% versus -4880.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GYRE-44.24%STTK+119.70%
+314%+125%-64%
Nov 21, 20251 yearNov 20, 2026
GYRE-78.58%STTK-52.55%
+59%-20%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GYRE versus STTK key metrics
MetricGYRESTTK
Share price$4.21$4.46
Market cap$460.79M$454.22M
1-day change-6.86%-1.98%
YTD return-40.37%+22.19%
1-year return-44.24%+119.70%
5-year return-77.55%-51.99%
Forward P/E70.17—
EPS (TTM)$-0.31$-0.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$116.59M$1.00M
Revenue growth (YoY)+10.24%-82.52%
Net income (latest FY)$9.88M$-48.81M
Gross margin95.35%—
Operating margin9.85%-5150.80%
Net margin8.47%-4880.90%
52-week high$9.14$8.33
52-week low$3.97$1.93
Distance from 52-week high-53.94%-46.46%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+343.47%+245.29%
Average volume181.04K1.20M
Shares outstanding109.45M101.84M
Employees62540
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • STTK has outperformed GYRE by 163.9 percentage points over the past year.
  • Gyre Therapeutics is more profitable, keeping 8.5 cents of every revenue dollar as net income versus -4880.9 cents for Shattuck Labs.
  • Gyre Therapeutics grew revenue faster in its latest fiscal year (+10.24% vs -82.52%).

About Gyre Therapeutics

GYRE stock →

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees

About Shattuck Labs

STTK stock →

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

GYRE vs STTK FAQ

Which is bigger, Gyre Therapeutics or Shattuck Labs?

Gyre Therapeutics (GYRE) is larger, with a market capitalization of $460.79M compared with $454.22M for Shattuck Labs (STTK).

Which stock has performed better over the past year, GYRE or STTK?

STTK returned +119.70% over the past 12 months, compared with -44.24% for GYRE (price return, excluding dividends). Past performance does not predict future results.

Are Gyre Therapeutics and Shattuck Labs in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons